ArticleMolecular and cellular biology2003
Targeted disruption of the mouse Mel(1b) melatonin receptor.
Article in Molecular and cellular biology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 237 citations in OpenAlex.
- Melatonin and aggressive behavior: A systematic review of the literature on preclinical and clinical evidence.Journal of pineal research · 2022Pooled it
- Melatonin reduces tachycardia in postural tachycardia syndrome: a randomized, crossover trial.Cardiovascular therapeutics · 2014Trial
- Effects of the melatonin MT-1/MT-2 agonist ramelteon on daytime body temperature and sleep.Sleep · 2010Trial
- Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.Sleep · 2009Trial
- Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD.Sleep & breathing = Schlaf & Atmung · 2008Trial
- Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea.Sleep & breathing = Schlaf & Atmung · 2007Trial
- Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2007Trial
- Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans.The Journal of physiology · 2004Trial
- Attention to Innate Circadian Rhythm and the Impact of Its Disruption on Diabetes.Diabetes & metabolism journal · 2024Review
- Melatonin's role in the timing of sleep onset is conserved in nocturnal mice.Npj biological timing and sleep · 2024Article
- Melatonin as a Coadjuvant in the Treatment of Patients with Fibromyalgia.Biomedicines · 2023Review
- Melatonin as a Chronobiotic with Sleep-promoting Properties.Current neuropharmacology · 2023Review
- Novel Therapeutics for Treating Sleep Disorders: New Perspectives onInternational journal of molecular sciences · 2022Article
- Potential effects of shift work on skin autoimmune diseases.Frontiers in immunology · 2022Review
- Evidence for the Benefits of Melatonin in Cardiovascular Disease.Frontiers in cardiovascular medicine · 2022Review
- The Role of the Melatoninergic System in Circadian and Seasonal Rhythms-Insights From Different Mouse Strains.Frontiers in physiology · 2022Review
- Membrane Melatonin Receptors Activated Cell Signaling in Physiology and Disease.International journal of molecular sciences · 2021Review
- Circadian Synchrony: Sleep, Nutrition, and Physical Activity.Frontiers in network physiology · 2021Article
- Biological Timing and Neurodevelopmental Disorders: A Role for Circadian Dysfunction in Autism Spectrum Disorders.Frontiers in neuroscience · 2021Review
- Melatonin Alleviates Acute Sleep Deprivation-Induced Memory Loss in Mice by Suppressing Hippocampal Ferroptosis.Frontiers in pharmacology · 2021Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Two high-affinity, G protein-coupled melatonin receptor subtypes have been identified in mammals. Targeted disruption of the Mel(1a) melatonin receptor prevents some, but not all, responses to the hormone, suggesting functional redundancy among receptor subtypes (Liu et al., Neuron 19:91-102, 1997). In the present work, the mouse Mel(1b) melatonin receptor cDNA was isolated and characterized, and the gene has been disrupted. The cDNA encodes a receptor with high affinity for melatonin and a pharmacological profile consistent with its assignment as encoding a melatonin receptor. Mice with targeted disruption of the Mel(1b) receptor have no obvious circadian phenotype. Melatonin suppressed multiunit electrical activity in the suprachiasmatic nucleus (SCN) in Mel(1b) receptor-deficient mice as effectively as in wild-type controls. The neuropeptide, pituitary adenylyl cyclase activating peptide, increases the level of phosphorylated cyclic AMP response element binding protein (CREB) in SCN slices, and melatonin reduces this effect. The Mel(1a) receptor subtype mediates this inhibitory response at moderate ligand concentrations (1 nM). A residual response apparent in Mel(1a) receptor-deficient C3H mice at higher melatonin concentrations (100 nM) is absent in Mel(1a)-Mel(1b) double-mutant mice, indicating that the Mel(1b) receptor mediates this effect of melatonin. These data indicate that there is a limited functional redundancy between the receptor subtypes in the SCN. Mice with targeted disruption of melatonin receptor subtypes will allow molecular dissection of other melatonin receptor-mediated responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.